Loading
A phase 3 trial testing HB1801 in HER2-positive breast cancer, active and no longer recruiting.
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer is a phase 3 interventional study registered as NCT06747338, led by Shanghai JMT-Bio, and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Open-label, Multicenter, Phase III Clinical Trial to Compare the Efficacy and Safety of KN026 Combined With HB1801 ± Carboplatin Versus Trastuzumab Combined With Pertuzumab and Docetaxel ± Carboplatin in Neoadjuvant Treatment of Early or Locally Advanced HER2-positive Breast Cancer. Planned enrolment is 520 participants (estimated). The study started in 2024-12-16 and primary completion is expected in 2026-12-16. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HB1801, KN026, CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares HB1801, CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares KN026, CSPC Pharmaceutical Group.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/